Skip to main content

Table 1 Baseline characteristics of patients by infection group

From: Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon

  HIV monoinfected patients (n = 134) HBV or HCV coinfected patients (n = 35) p
Women (no.) 91 (68%) 22 (63%) 0.6
Age (years)      
   Median (IQR) 34.5 (28.4-39.7) 41.6 (33.7-48.8) <0.001
   <42 (no.) 113 (84%) 19 (54%) <0.001
Time since diagnosis of HIV seropositivity (months)      
   Median (IQR) 29.4 (13.5-53.4) 22.1 (8.3-43.6) 0.2
   <24 (no.) 56 (42%) 18 (51%) 0.3
Body weight (Kg) [median (IQR)] 65 (55-70) 63 (54-70) 0.7
Body mass index (Kg/m2)*      
   median (IQR) 23.2 (21.6-24.7) 22.2 (20.6-25.6) 0.2
   ≥ 21 (no.) 108 (82%) 25 (74%) 0.3
Karnofsky score >90% (no.) 72 (54%) 15 (43%) 0.3
CDC clinical stage (no.)      0.7
   A 19 (14%) 4 (11%)  
   B 58 (43%) 13 (37%)  
   C 57 (43%) 18 (51%)  
CD4 cell count (/mm3)      
   Median (IQR) 138 (67-222) 135 (68-216) 0.7
   <100 (no.) 80 (60%) 22 (63%) 0.7
HIV-1 viral load (log10 copies/mL)      
   Median (IQR) 5.3 (4.7-5.5) 5.3 (4.8-5.7) 0.5
   <5.0 (no.) 50 (37%) 11 (31%) 0.5
Hemoglobin (g/dL)      
   Median (IQR) 11.0 (9.8-12.1) 11.1 (9.8-12.9) 0.6
   <10 (no.) 36 (27%) 10 (29%) 0.8
Total lymphocyte count (/mm3)      
   Median (IQR) 1578 (1080-2100) 1408 (1000-1900) 0.4
   <1700 (no.) 77 (57%) 23 (66%) 0.4
ALT level (×ULN)      
   Median (IQR) 0.6 (0.4-0.7) 0.8 (0.6-1.2) <0.001
   ≥ 1.25 (no.) 8 (6%) 8 (30%) 0.002
ASAT (×ULN)      
   Median (IQR) 0.8 (0.6-1.1) 1.3 (0.9-1.7) <0.001
   ≥ 1.25 (no.) 21 (17%) 17 (52%) <0.001
History of antiretroviral treatment (no.)      0.6
   None 131 (98%) 34 (97%)  
   HAART 1 (1%) 1 (3%)  
   Nevirapine (PMTCT) 2 (2%) 0 -  
Baseline antiretroviral treatment (no.)      0.3
   Zidovudine+lamivudine+nevirapine 70 (52%) 15 (43%)  
   Stavudine+lamivudine+nevirapine 64 (48%) 20 (57%)  
Cotrimoxazole prophylaxis (no.) 124 (93%) 35 (100%) 0.1
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; PMTCT, prevention of mother-to-child transmission; HAART, highly active antiretroviral therapy
  2. * 3 missing values; 1 missing value; 9 missing values